A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

समान संसाधन

• Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
  द्वारा: Aherne, G. W., और अन्य
  प्रकाशित: (1998)
• Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
  द्वारा: Jackman, A. L., और अन्य
  प्रकाशित: (1995)
• Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
  द्वारा: Judson, I., और अन्य
  प्रकाशित: (1998)
• Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
  द्वारा: Freemantle, S. J., और अन्य
  प्रकाशित: (1995)
• New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
  द्वारा: Blackledge, G.
  प्रकाशित: (1998)